Published in Nat Med on April 20, 2008
Race, socioeconomic status, and health: complexities, ongoing challenges, and research opportunities. Ann N Y Acad Sci (2010) 4.50
G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol Ther (2011) 2.13
High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy. Circulation (2012) 1.85
The A's, G's, C's, and T's of health disparities. BMC Med Genomics (2009) 1.75
Epidemiology and pathophysiology of Takotsubo syndrome. Nat Rev Cardiol (2015) 1.66
Capturing adenylyl cyclases as potential drug targets. Nat Rev Drug Discov (2009) 1.66
Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res (2013) 1.62
G protein-coupled receptor kinase 2 expression and activity are associated with blood pressure in black Americans. Hypertension (2009) 1.62
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
Common variants in HSPB7 and FRMD4B associated with advanced heart failure. Circ Cardiovasc Genet (2010) 1.51
A loss-of-function variant of PTPN22 is associated with reduced risk of systemic lupus erythematosus. Hum Mol Genet (2008) 1.43
Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol (2009) 1.42
Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev (2009) 1.40
Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation. Proc Natl Acad Sci U S A (2011) 1.33
G protein-coupled receptor kinases in normal and failing myocardium. Front Biosci (Landmark Ed) (2011) 1.17
G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ Res (2011) 1.14
Nuclear effects of G-protein receptor kinase 5 on histone deacetylase 5-regulated gene transcription in heart failure. Circ Heart Fail (2011) 1.12
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics (2011) 1.12
Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther (2011) 1.11
β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin (2012) 1.10
Cardiac signaling genes exhibit unexpected sequence diversity in sporadic cardiomyopathy, revealing HSPB7 polymorphisms associated with disease. J Clin Invest (2009) 1.10
Pharmacogenomics: the genetics of variable drug responses. Circulation (2011) 1.10
Determining the absolute requirement of G protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication. Circ Res (2012) 1.09
An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p. Cell Signal (2010) 1.05
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
β₂ AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol (2010) 1.00
Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure. Mol Pharmacol (2009) 1.00
Functional selectivity in adrenergic and angiotensin signaling systems. Mol Pharmacol (2010) 0.99
Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J (2012) 0.98
Genomics, transcriptional profiling, and heart failure. J Am Coll Cardiol (2009) 0.98
Nuclear translocation of cardiac G protein-Coupled Receptor kinase 5 downstream of select Gq-activating hypertrophic ligands is a calmodulin-dependent process. PLoS One (2013) 0.97
The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiol Rev (2015) 0.97
Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. J Mol Cell Cardiol (2010) 0.96
Pathobiology of cardiac dyssynchrony and resynchronization. Heart Rhythm (2009) 0.96
The genomic architecture of sporadic heart failure. Circ Res (2011) 0.95
Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol (2009) 0.94
Beta-adrenergic signaling in heart failure-adapt or die. Nat Med (2008) 0.94
Views on personalized medicine: do the attitudes of African American and white prescription drug consumers differ? Public Health Genomics (2009) 0.93
Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol (2014) 0.92
Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner. J Am Coll Cardiol (2012) 0.92
Race, common genetic variation, and therapeutic response disparities in heart failure. JACC Heart Fail (2014) 0.91
G protein-coupled receptor kinase-5 attenuates atherosclerosis by regulating receptor tyrosine kinases and 7-transmembrane receptors. Arterioscler Thromb Vasc Biol (2011) 0.91
Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther (2011) 0.89
Targeting G protein-coupled receptor kinases (GRKs) in Heart Failure. Drug Discov Today Dis Mech (2010) 0.88
GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics (2009) 0.87
Genetic variation, β-blockers, and perioperative myocardial infarction. Anesthesiology (2011) 0.87
Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor. Molecules (2014) 0.85
Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail (2012) 0.85
G protein-coupled receptor kinase 5 gene polymorphisms are associated with postoperative atrial fibrillation after coronary artery bypass grafting in patients receiving β-blockers. Circ Cardiovasc Genet (2014) 0.84
G protein-coupled receptor kinase 5 phosphorylates nucleophosmin and regulates cell sensitivity to polo-like kinase 1 inhibition. J Biol Chem (2012) 0.84
Clinical considerations of heritable factors in common heart failure. Circ Cardiovasc Genet (2011) 0.84
Pharmacogenetics in chronic heart failure: new developments and current challenges. Curr Heart Fail Rep (2012) 0.84
Akt2 deficiency promotes cardiac induction of Rab4a and myocardial β-adrenergic hypersensitivity. J Mol Cell Cardiol (2010) 0.84
Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases. Br J Pharmacol (2015) 0.84
Basic science of cardiac resynchronization therapy: molecular and electrophysiological mechanisms. Circ Arrhythm Electrophysiol (2012) 0.83
Chronic heart failure: beta-blockers and pharmacogenetics. Eur J Clin Pharmacol (2008) 0.83
Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics (2012) 0.83
Genotype-based risk and pharmacogenetic sampling in clinical trials. J Biopharm Stat (2010) 0.81
Protective effect of a GRK5 polymorphism on heart failure and its interaction with beta-adrenergic receptor antagonists. Pharmacogenomics (2008) 0.81
Genetic determinants of response to cardiovascular drugs. Curr Opin Cardiol (2012) 0.80
Atomic Structure of GRK5 Reveals Distinct Structural Features Novel for G Protein-coupled Receptor Kinases. J Biol Chem (2015) 0.80
Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. Heart Fail Clin (2010) 0.80
Change in mRNA Expression after Atenolol, a Beta-adrenergic Receptor Antagonist and Association with Pharmacological Response. Arch Drug Inf (2009) 0.79
Grk5l controls heart development by limiting mTOR signaling during symmetry breaking. Cell Rep (2013) 0.79
Pharmacogenetic profiling in the treatment of heart disease. Transl Res (2009) 0.79
Pharmacogenomics and cardiovascular disease. Curr Cardiol Rep (2013) 0.79
Length of day during early gestation as a predictor of risk for severe retinopathy of prematurity. Ophthalmology (2013) 0.79
Overlapping and opposing functions of G protein-coupled receptor kinase 2 (GRK2) and GRK5 during heart development. J Biol Chem (2014) 0.79
"Canonical and non-canonical actions of GRK5 in the heart". J Mol Cell Cardiol (2016) 0.78
Discussing race-related limitations of genomic testing for colon cancer risk: implications for education and counseling. Soc Sci Med (2014) 0.78
GRK2 in the heart: a GPCR kinase and beyond. Antioxid Redox Signal (2014) 0.78
Mapping genetic variants associated with beta-adrenergic responses in inbred mice. PLoS One (2012) 0.78
Applied pharmacogenomics in cardiovascular medicine. Annu Rev Med (2013) 0.78
Heart failure pharmacogenetics: past, present, and future. Curr Cardiol Rep (2011) 0.78
Clinical and genetic analysis of long QT syndrome in children from six families in Saudi Arabia: are they different? Pediatr Cardiol (2009) 0.78
Genetics and heart failure: a concise guide for the clinician. Curr Cardiol Rev (2015) 0.78
Genetic variation in alpha2-adrenoreceptors and heart rate recovery after exercise. Physiol Genomics (2015) 0.77
Molecular Mechanisms Linking Autonomic Dysfunction and Impaired Cardiac Contractility in Critical Illness. Crit Care Med (2016) 0.77
GRK5 Polymorphisms and Postoperative Atrial Fibrillation following Coronary Artery Bypass Graft Surgery. Sci Rep (2015) 0.77
Contextualizing Genetics for Regional Heart Failure Care. Curr Cardiol Rev (2016) 0.77
Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure. J Transl Med (2015) 0.77
Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdiscip Rev Syst Biol Med (2010) 0.77
Tailoring therapy for heart failure: the pharmacogenomics of adrenergic receptor signaling. Pharmgenomics Pers Med (2014) 0.77
Enhanced Uterine Contractility and Stillbirth in Mice Lacking G Protein-Coupled Receptor Kinase 6 (GRK6): Implications for Oxytocin Receptor Desensitization. Mol Endocrinol (2016) 0.77
RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications. World J Cardiol (2010) 0.77
Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev (2014) 0.76
Polymorphisms present in G-protein-coupled receptor kinases and their effect on β-blocker treatment. Pharmacogenomics (2011) 0.76
Association of an intronic, but not any exonic, FRMD4B sequence variant and heart failure. Clin Transl Sci (2010) 0.76
Social Determinants of Racial Disparities in CKD. J Am Soc Nephrol (2016) 0.76
Molecular assembly of rhodopsin with G protein-coupled receptor kinases. Cell Res (2017) 0.75
Association of a common KCNE1 variant with heart failure. Heart Rhythm (2009) 0.75
Progress toward genetic tailoring of heart failure therapy. Curr Opin Mol Ther (2010) 0.75
Graves' disease presenting as bi-ventricular heart failure with severe pulmonary hypertension and pre-eclampsia in pregnancy--a case report and review of the literature. BMC Res Notes (2014) 0.75
G protein-coupled receptor kinase 5: exploring its hype in cardiac hypertrophy. Circ Res (2012) 0.75
Adverse subpopulation regression for multivariate outcomes with high-dimensional predictors. Stat Med (2012) 0.75
G Protein-Coupled Receptor Kinases: Crucial Regulators of Blood Pressure. J Am Heart Assoc (2016) 0.75
The analysis of heterotaxy patients reveals new loss-of-function variants of GRK5. Sci Rep (2016) 0.75
Pharmacogenomics of hypertension and heart disease. Curr Hypertens Rep (2015) 0.75
The expanding GRK interactome: Implications in cardiovascular disease and potential for therapeutic development. Pharmacol Res (2016) 0.75
Cardiovascular Pharmacogenomics-Implications for Patients With CKD. Adv Chronic Kidney Dis (2016) 0.75
Inference of population structure using multilocus genotype data. Genetics (2000) 147.76
Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 14.72
Long-term trends in the incidence of and survival with heart failure. N Engl J Med (2002) 10.37
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet (1999) 10.07
Trends in heart failure incidence and survival in a community-based population. JAMA (2004) 8.90
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med (1984) 6.74
Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med (2002) 5.50
Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation (1993) 4.52
Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science (1995) 4.18
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med (2001) 4.07
Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A (1997) 3.89
Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation (2000) 3.85
beta-adrenergic receptor blockade in chronic heart failure. Circulation (2000) 3.43
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet (1993) 3.20
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A (2006) 2.72
Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol Pharmacol (2003) 2.55
Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling. Proc Natl Acad Sci U S A (2005) 2.48
Cardiac-specific ablation of G-protein receptor kinase 2 redefines its roles in heart development and beta-adrenergic signaling. Circ Res (2006) 2.08
Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. Neuron (1999) 2.03
Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. Proc Natl Acad Sci U S A (1996) 1.70
Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol (2001) 1.70
Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. Circ Res (1994) 1.66
Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci U S A (2003) 1.64
Identification, purification, and characterization of GRK5, a member of the family of G protein-coupled receptor kinases. J Biol Chem (1994) 1.57
Cardiomyopathies: from genetics to the prospect of treatment. Lancet (2001) 1.54
Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. J Clin Invest (1999) 1.39
Altered patterns of agonist-stimulated cAMP accumulation in cells expressing mutant beta 2-adrenergic receptors lacking phosphorylation sites. Mol Pharmacol (1989) 1.37
Why does the myocardium fail? Insights from basic science. Lancet (1998) 1.35
Examining population stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol Biomarkers Prev (2005) 1.33
Regulation of cardiac contractility by Rab4-modulated beta2-adrenergic receptor recycling. Proc Natl Acad Sci U S A (2004) 1.28
Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol (1998) 1.16
Beta-adrenergic receptors in the failing heart: the good, the bad, and the unknown. J Clin Invest (2001) 1.05
Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res (2000) 1.04
Myocardial function in hearts with transgenic overexpression of the G protein-coupled receptor kinase 5. Ann Thorac Surg (2001) 1.02
A single, sequential, genome-wide test to identify simultaneously all promising areas in a linkage scan. Genet Epidemiol (2000) 1.02
Pharmacogenetic applications of the Human Genome project. Nat Med (2001) 1.00
Current role of beta-adrenergic blockers in the management of chronic heart failure. Am J Med (2001) 0.99
Characterization of lymphocyte beta 2-adrenoceptor signalling in patients with left ventricular volume overload disease. Clin Exp Pharmacol Physiol (2002) 0.99
Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure. Mol Cell Biochem (2004) 0.93
Angiotensin converting enzyme inhibitors attenuated the expression of G-protein coupled receptor kinases in heart failure patients. Circ J (2006) 0.90
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature (2005) 11.22
Telemonitoring in patients with heart failure. N Engl J Med (2010) 10.82
Sequence variants in SLITRK1 are associated with Tourette's syndrome. Science (2005) 8.20
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA (2007) 7.12
Trends in survival after in-hospital cardiac arrest. N Engl J Med (2012) 5.67
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med (2002) 5.50
Seven-transmembrane-spanning receptors and heart function. Nature (2002) 5.38
Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA (2006) 5.06
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 4.56
Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res (2007) 4.53
Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet (2004) 4.51
Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
Appropriateness of percutaneous coronary intervention. JAMA (2011) 4.33
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
Serum potassium levels and mortality in acute myocardial infarction. JAMA (2012) 4.09
Recent national trends in readmission rates after heart failure hospitalization. Circ Heart Fail (2009) 3.95
Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). J Am Coll Cardiol (2013) 3.90
Long-term outcomes in elderly survivors of in-hospital cardiac arrest. N Engl J Med (2013) 3.85
Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res (2002) 3.62
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science (2013) 3.60
Exploring the public understanding of basic genetic concepts. J Genet Couns (2004) 3.53
Automated external defibrillators and survival after in-hospital cardiac arrest. JAMA (2010) 3.36
Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA (2008) 3.30
Hospital variation in time to defibrillation after in-hospital cardiac arrest. Arch Intern Med (2009) 3.27
Contraindicated initiation of β-blocker therapy in patients hospitalized for heart failure. JAMA Intern Med (2013) 3.26
Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation (2008) 3.19
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation (2002) 3.15
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol (2002) 3.05
The concept of risk in comparative-effectiveness research. N Engl J Med (2014) 3.04
A novel and efficient model of coronary artery ligation and myocardial infarction in the mouse. Circ Res (2010) 3.00
Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res (2011) 2.99
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99
Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. J Biol Chem (2010) 2.93
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation (2005) 2.85
Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med (2003) 2.83
Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 2.83
Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry. Circ Cardiovasc Qual Outcomes (2011) 2.77
RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab (2003) 2.72
Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation (2009) 2.70
Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation (2003) 2.70
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res (2005) 2.67
Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell (2007) 2.65
Racial differences in survival after in-hospital cardiac arrest. JAMA (2009) 2.65
Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. J Am Coll Cardiol (2010) 2.62
Concordance of physician ratings with the appropriate use criteria for coronary revascularization. J Am Coll Cardiol (2011) 2.62
Measuring performance for treating heart attacks and heart failure: the case for outcomes measurement. Health Aff (Millwood) (2007) 2.62
Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest (2003) 2.56
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
The National Cardiovascular Data Registry (NCDR) Data Quality Brief: the NCDR Data Quality Program in 2012. J Am Coll Cardiol (2012) 2.50
Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol (2010) 2.49
Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med (2007) 2.48
Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA (2009) 2.42
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol (2006) 2.41
MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res (2009) 2.40
All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol (2009) 2.40
Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord (2004) 2.34
Multiple genes for essential-hypertension susceptibility on chromosome 1q. Am J Hum Genet (2006) 2.34
Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction. JAMA (2010) 2.33
Phenotyping hypertrophy: eschew obfuscation. Circ Res (2003) 2.32
MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res (2011) 2.32
A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest (2003) 2.32
Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res (2012) 2.31
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol (2005) 2.31
Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J (2005) 2.29
Diagnostic blood loss from phlebotomy and hospital-acquired anemia during acute myocardial infarction. Arch Intern Med (2011) 2.29
Mitochondrial fusion is essential for organelle function and cardiac homeostasis. Circ Res (2011) 2.27
Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice. J Clin Invest (2007) 2.23